EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study

Arvid Engström iD, Jonas Söderling, Anders Hviid iD, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Björn Pasternak iD, Peter Ueda

European Heart Journal - Cardiovascular Pharmacotherapy · 14.08.2024 · 10 (5) · 432-443

DOI: 10.1093/ehjcvp/pvae045 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 25.06.2024. Verfasst von Arvid Engström und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Solna, Stockholm 171 77, Sweden. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucosides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Heart-Lung Foundation, Diabetesförbundet, Karolinska Institutet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To assess the comparative cardiovascular and renal effectiveness and safety of empagliflozin vs. dapagliflozin among patients with type 2 diabetes in routine clinical practice. Methods and results Cohort study using data from nationwide registers in Sweden, Denmark, and Norway, from June 2014 to June 2021 included 141 065 new users of empagliflozin and 58 306 new users of dapagliflozin. Coprimary outcomes were major cardiovascular events (myocardial infarction, stroke, and cardiovascular death), heart failure (hospitalization or death because of heart failure) and serious renal events (renal replacement therapy, hospitalization for renal events, and death from renal causes). Secondary outcomes were the individual components of the primary outcomes, any cause death, and diabetic ketoacidosis. Use of empagliflozin vs. dapagliflozin was associated with similar risk of major cardiovascular events [adjusted incidence rate: 15.9 vs. 15.8 events per 1000 person-years; HR 1.02, (95% confidence interval 0.97–1.08)], heart failure [6.5 vs. 6.3 events per 1000 person-years; HR 1.05 (0.97–1.14)] and serious renal events [3.7 vs. 4.1 events per 1000 person-years; HR 0.97 (0.87–1.07)]. In secondary outcome analyses, the HRs for use of empagliflozin vs. dapagliflozin were 1.00 (0.93–1.07) for myocardial infarction, 1.03 (0.95–1.12) for stroke, 1.01 (0.92–1.13) for cardiovascular death, 1.06 (1.00–1.11) for any cause death, 0.77 (0.60–0.99) for renal replacement therapy, 1.20 (0.75–1.93) for renal death, 1.01 (0.90–1.12) for hospitalization for renal events and 1.12 (0.94–1.33) for diabetic ketoacidosis.

Conclusion

Use of empagliflozin and dapagliflozin was associated with similar risk of cardiovascular and renal outcomes, mortality, and diabetic ketoacidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsCardiovascular DiseasesDiabetes Mellitus, Type 2GlucosidesSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedDenmarkDiabetic KetoacidosisDiabetic NephropathiesIncidenceRegistriesRisk AssessmentRisk FactorsScandinavian and Nordic CountriesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Chronic kidney diseaseComparative effectivenessDapagliflozinDiabetic ketoacidosisEmpagliflozinHeart failureSGLT2 inhibitors

Substanzen

Benzhydryl CompoundsdapagliflozinempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Solna, Stockholm 171 77, Sweden.
  • Department of Epidemiology Research, Statens Serum Institut, DK-2300 Copenhagens, Denmark.
  • Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1165 Copenhagen, Denmark.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg 405 30, Sweden.
  • The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg 413 45, Sweden.
  • HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Science, NTNU-Norwegian University of Science and Technology, Trondheim NO-7491, Norway.

ORCID-Profile: Arvid Engström, Anders Hviid, Björn Pasternak

Förderung

  • Swedish Heart-Lung Foundation
  • Diabetesförbundet
  • Karolinska Institutet
  • Novo Nordisk Foundation

Zitieren

APA

Engström, A., Söderling, J., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Wintzell, V., Hveem, K., Jonasson, C., Melbye, M., Pasternak, B., & Ueda, P. (2024). Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 10(5), 432-443. https://doi.org/10.1093/ehjcvp/pvae045

Vancouver

Engström A, Söderling J, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, et al. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 2024;10(5):432-443. doi:10.1093/ehjcvp/pvae045

BibTeX
@article{Engstrm2024,
  author = {Engström, Arvid and Söderling, Jonas and Hviid, Anders and Eliasson, Björn and Gudbjörnsdottir, Soffia and Wintzell, Viktor and Hveem, Kristian and Jonasson, Christian and Melbye, Mads and Pasternak, Björn and Ueda, Peter},
  title = {Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  volume = {10},
  number = {5},
  pages = {432--443},
  doi = {10.1093/ehjcvp/pvae045}
}
Kostenlos starten →